KYORIN Pharmaceutical Co., Ltd.
Concluded License Agreement for EB05, a Candidate Therapeutic for ARDS (Acute Respiratory Distress Syndrome)
Entered an exclusive license agreement with Edesa Biotech for the development and commercial rights in Japan for EB05, an ARDS therapeutic candidate. Upfront payment of 12 million USD, milestone payments up to 134 million USD, and tiered royalties established. KYORIN will be responsible for clinical trials in Japan. The upfront payment is expected to be recorded in consolidated results for the fiscal year ending March 2027.
Key Figures
- Upfront payment: 12 million USD
- Milestones: up to 134 million USD
- Royalties: Tiered
- Scope: Exclusive development and commercialization rights for EB05 in Japan
- Timing of impact: To be recorded in consolidated results for the fiscal year ending March 2027
AI要約
Transaction Overview
KYORIN Pharmaceutical Co., Ltd. has entered into a license agreement to acquire exclusive rights for the development and commercialization in Japan of EB05, an ARDS therapeutic candidate from Edesa Biotech. An upfront payment of 12 million USD will be made, and milestone payments up to 134 million USD will be payable from development through drug price listing. Tiered royalties based on net sales are also established. KYORIN will be responsible for conducting clinical trials in Japan and aims for product launch.
Impact and Future Developments
This agreement advances the mid-term plan to expand the development pipeline through proactive investment in in-licensing. The upfront payment will be recorded as research and development expense in the consolidated results for the fiscal year ending March 2027. EB05 is an antibody therapy targeting TLR4 intended to improve survival in ARDS. Future development progress and publication of clinical data will be closely watched.
KYORIN Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
